Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
2.210
-0.080 (-3.49%)
Mar 20, 2026, 3:31 PM EDT - Market open
Veru Inc. Employees
Veru Inc. had 20 employees as of September 30, 2025. The number of employees decreased by 190 or -90.48% compared to the previous year.
Employees
20
Change (1Y)
-190
Growth (1Y)
-90.48%
Revenue / Employee
n/a
Profits / Employee
-$955,676
Market Cap
35.47M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 20 | -190 | -90.48% | 20 | 0 |
| Sep 30, 2024 | 210 | 21 | 11.11% | 210 | 0 |
| Sep 30, 2023 | 189 | -44 | -18.88% | 189 | 0 |
| Sep 30, 2022 | 233 | -19 | -7.54% | 233 | 0 |
| Sep 30, 2021 | 252 | -87 | -25.66% | 252 | 0 |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| NextCure | 40 |
| Werewolf Therapeutics | 39 |
| Palatin Technologies | 29 |
| LeonaBio | 26 |
| Sensei Biotherapeutics | 15 |
| CervoMed | 15 |
| Rein Therapeutics | 11 |
VERU News
- 11 days ago - Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss - GlobeNewsWire
- 6 weeks ago - Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th - GlobeNewsWire
- 3 months ago - Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress - GlobeNewsWire
- 3 months ago - Veru to Report Fiscal Year 2025 Financial Results on December 17th - GlobeNewsWire
- 5 months ago - Veru to Present Two Abstracts at ObesityWeek 2025 - GlobeNewsWire
- 5 months ago - Veru Announces Proposed Public Offering - GlobeNewsWire
- 6 months ago - Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity - GlobeNewsWire
- 7 months ago - Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress - GlobeNewsWire